Trials / Conditions / Refractory Hepatoblastoma

Refractory Hepatoblastoma

14 registered clinical trials studyying Refractory Hepatoblastoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative NCT05556642	Children's Hospital Medical Center, Cincinnati	—
Recruiting	Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors NCT04851119	Children's Oncology Group	Phase 1 / Phase 2
Recruiting	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma NCT04901702	St. Jude Children's Research Hospital	Phase 1 / Phase 2
Active Not Recruiting	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders Wi NCT03698994	National Cancer Institute (NCI)	Phase 2
Completed	Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Ly NCT03526250	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or H NCT03210714	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hi NCT03213652	National Cancer Institute (NCI)	Phase 2
Completed	Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Hist NCT03233204	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or NCT03213704	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanc NCT03155620	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wi NCT02867592	National Cancer Institute (NCI)	Phase 2